Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price increased by investment analysts at Citigroup from $160.00 to $184.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target would suggest a potential upside of 113.80% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Citizens Jmp reiterated a “market outperform” rating and issued a $137.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $195.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, Royal Bank Of Canada lifted their price target on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an “outperform” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $145.62.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded up $0.05 during trading on Monday, reaching $86.06. 1,211,627 shares of the company’s stock were exchanged, compared to its average volume of 856,101. The stock has a market capitalization of $5.59 billion, a PE ratio of -5.91 and a beta of 0.61. The firm’s fifty day moving average price is $95.08 and its 200-day moving average price is $100.97. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.12) EPS. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at $19,187,339.20. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 98,499 shares of company stock worth $9,797,834. Company insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new stake in Mirum Pharmaceuticals in the second quarter worth $691,672,000. BlackRock Inc. purchased a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $513,945,000. William Blair Investment Management LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter valued at $164,453,000. Janus Henderson Group PLC grew its holdings in shares of Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Mirum Pharmaceuticals during the second quarter worth approximately $78,434,000.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum said LIVMARLI met the primary endpoint in the Phase 3 EXPAND study evaluating treatment for cholestatic pruritus associated with ultra-rare cholestatic liver diseases. The result supports the company’s efforts to expand LIVMARLI beyond its existing commercial uses. Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
• Positive Sentiment: The company reported positive topline Phase 3 results and plans to submit an application to the U.S. Food and Drug Administration in 2027. A successful filing and potential approval could broaden LIVMARLI’s addressable market and provide a future revenue catalyst. Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results; Plans FDA Filing In 2027
• Positive Sentiment: HC Wainwright raised its price target for MIRM to $200 from $195 while maintaining a Buy rating, signaling increased confidence in the company’s valuation following the clinical update.
• Neutral Sentiment: Mirum hosted an investor discussion covering the EXPAND study results, while earlier reports had highlighted the planned release of the data. These events provided additional visibility but did not represent separate clinical catalysts. Mirum Investor Call Announcement
• Neutral Sentiment: The planned FDA submission is not expected until 2027, leaving regulatory review, approval and commercial execution as important future uncertainties. Recent earnings also showed a loss despite revenue growth, underscoring Mirum’s continuing profitability risk.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.